Atossa Genetics Inc (NASDAQ:ATOS) is having yet another incredible day in the market today as investors continue to focus on the company’s plans to attack breast cancer. Of course, our partners at Trade Ideas were the first to alert us to today’s gains. Currently (9:12), ATOS is trading at $0.55 per share after a gain of $0.02 per share (4.08%) thus far today.
ATOS Continues Upward On Breast Cancer News
As mentioned above, Atossa Genetics is having an incredibly strong day in the market today, following up on recent gains that we’ve seen from the stock. The skyward movement all started on October 2nd, when the company released news that it plans to attack breast cancer.
In the press release offered up early this week, ATOS announced that it has begun a new program that uses Chemeric Antigen Receptor Therapy, also known as CAR-T. The company plans to use its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast. The idea is that this will prove to be a positive treatment for breast cancer.
The novel approach taken by ATOS uses its proprietary intraductal microcatheter technology for the potential transpapillary, also known as TRAP, delivery of T-cells. These cells have been genetically modified to attack breast cancer cells. It is believed by the company that this method has several advantages, including:
- Toxicity Reduction – Achieved by limiting systemic exposure of the T-cells used in the treatment.
- Improved Efficacy – Achieved by placing the T-cells in direct contact with the target ductal epithelial cells that are currently undergoing malignant transformation.
- Activity Extension – Achieved through lymphatic migration of the CAR-T cells along the same path taken by migrating cancer cells. It is believed that this will extend the cytotoxic actions into the regional lymph system, ultimately limiting tumor cell dissemination.
In a statement, Steven Quay, MD, PhD, CEO at ATOS, had the following to offer:
“We have been encouraged by the promise that CAR-T has shown in other forms of cancer, which is usually delivered systemically. We believe that our proprietary TRAP technology could provide a potentially safer yet effective method to deliver CAR-T… We believe that TRAP CAR-T, as we are calling this novel approach to adaptive T-cell therapy in breast cancer, will provide another approach to breast cancer, and that it may be particularly well-suited for the deadlier forms of breast cancer such as ‘triple negative.’ Now that we have developed a foundational intellectual property position with respect to TRAP CAR-T, we intend to continue research and development through partnership with leading investigators, institutions, and organizations around the world, bringing atossa’s technology and expertise in TRAP delivery together with experts in cancer immunology and T-cell biology. Multiple studies in both animals and humans have shown that a number of therapies can be delivered by the TRAP, intraductal route.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ATOS. In particular, we’re interested in following the progress with regard to TRAP CAR-T, and excited to see the results as the study gets underway. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!